Literature DB >> 27683821

Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C.

Julia Hengst1, Christine Susanne Falk2,3,4, Verena Schlaphoff1, Katja Deterding1, Michael Peter Manns1,3,4, Markus Cornberg1,4, Heiner Wedemeyer1,2,3.   

Abstract

BACKGROUND: Persistent infection with hepatitis C virus (HCV) causes profound alterations of the cytokine and chemokine milieu in peripheral blood. However, it is unknown to what extend these alterations affect the progression of liver disease and whether HCV clearance normalizes soluble inflammatory mediators.
METHODS: We performed multianalyte profiling of 50 plasma proteins in 28 patients with persistent HCV infection and advanced stages of liver fibrosis or cirrhosis and 20 controls with fatty liver disease. The patients were treated for 24 weeks with sofosbuvir and ribavirin and underwent sampling longitudinally. Ten patients experienced viral relapse after treatment cessation.
RESULTS: The cytokine and chemokine expression pattern was markedly altered in patients with chronic HCV infection as compared to healthy controls and patients with nonalcoholic steatohepatitis. Distinct soluble factors were associated with the level of fibrosis/cirrhosis, viral replication, or treatment outcome. The baseline expression level of 10 cytokines distinguished patients with a sustained viral response from those who experienced viral relapse. While the majority of upregulated analytes declined during and after successful therapy, HCV clearance did not lead to a restoration of parameters that were suppressed.
CONCLUSIONS: Chronic HCV infection appears to disrupt the milieu of soluble inflammatory mediators even after viral clearance. Thus, HCV cure does not lead to complete immunological restitution.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  DAA; HCV; chemokines; chronic hepatitis C; cirrhosis; cytokines; direct-acting antiviral; soluble immune mediators

Mesh:

Substances:

Year:  2016        PMID: 27683821     DOI: 10.1093/infdis/jiw457

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  44 in total

1.  Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells.

Authors:  Joana Dias; Julia Hengst; Tiphaine Parrot; Edwin Leeansyah; Sebastian Lunemann; David F G Malone; Svenja Hardtke; Otto Strauss; Christine L Zimmer; Lena Berglin; Thomas Schirdewahn; Sandra Ciesek; Nicole Marquardt; Thomas von Hahn; Michael P Manns; Markus Cornberg; Hans-Gustaf Ljunggren; Heiner Wedemeyer; Johan K Sandberg; Niklas K Björkström
Journal:  J Hepatol       Date:  2019-05-14       Impact factor: 25.083

2.  Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

Review 3.  Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection.

Authors:  Barbara Rehermann; Robert Thimme
Journal:  Gastroenterology       Date:  2018-09-26       Impact factor: 22.682

4.  Early occurrence and recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after sustained virological response.

Authors:  Tatsuo Kanda; Shunichi Matsuoka; Mitsuhiko Moriyama
Journal:  Hepatol Int       Date:  2018-04-04       Impact factor: 6.047

5.  Intra-Hepatic Depletion of Mucosal-Associated Invariant T Cells in Hepatitis C Virus-Induced Liver Inflammation.

Authors:  Fabian J Bolte; Ashley C O'Keefe; Lauren M Webb; Elisavet Serti; Elenita Rivera; T Jake Liang; Marc Ghany; Barbara Rehermann
Journal:  Gastroenterology       Date:  2017-08-02       Impact factor: 22.682

6.  De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.

Authors:  Allison J Kwong; W Ray Kim; Jennifer A Flemming
Journal:  Hepatology       Date:  2018-10       Impact factor: 17.425

Review 7.  Designing an HCV vaccine: a unique convergence of prevention and therapy?

Authors:  Christopher M Walker
Journal:  Curr Opin Virol       Date:  2017-05-25       Impact factor: 7.090

Review 8.  Current progress in host innate and adaptive immunity against hepatitis C virus infection.

Authors:  Jijing Shi; Yuanyuan Li; Wenxian Chang; Xuexiu Zhang; Fu-Sheng Wang
Journal:  Hepatol Int       Date:  2017-06-22       Impact factor: 6.047

9.  Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals.

Authors:  Saverio G Parisi; Samantha Andreis; Monica Basso; Silvia Cavinato; Renzo Scaggiante; Marzia Franzetti; Massimo Andreoni; Giorgio Palù; Anna Maria Cattelan
Journal:  Med Microbiol Immunol       Date:  2017-09-01       Impact factor: 3.402

10.  HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection.

Authors:  Solomon Owusu Sekyere; Bernhard Schlevogt; Friederike Mettke; Mohammad Kabbani; Katja Deterding; Thomas Christian Wirth; Arndt Vogel; Michael Peter Manns; Christine Susanne Falk; Markus Cornberg; Heiner Wedemeyer
Journal:  Liver Cancer       Date:  2018-07-18       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.